Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Relapsed/Refractory DLBCL
NCT01078922Phase 2Terminated
- Sponsor
- Oncology Specialists
- Start
- Feb 2010
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Oncology Specialists. Started Feb 2010; status: terminated.
02
Drugs
ofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01078922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01078922.